Mark Lambie

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5403863/publications.pdf

Version: 2024-02-01

304743 223800 2,279 65 22 46 h-index citations g-index papers 67 67 67 2789 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Outcome measures for technique survival reported in peritoneal dialysis: A systematic review. Peritoneal Dialysis International, 2022, 42, 279-287.	2.3	9
2	How do patients and their family members experience the transition from peritoneal dialysis to incentre haemodialysis? A multisite qualitative study in England and Australia. Peritoneal Dialysis International, 2022, 42, 297-304.	2.3	3
3	Widening access to the specialised foundation programme. British Journal of Hospital Medicine (London, England: 2005), 2022, 83, 1-7.	0.5	1
4	Mortality Trends After Transfer From Peritoneal Dialysis to Hemodialysis. Kidney International Reports, 2022, 7, 1062-1073.	0.8	12
5	Risk factors associated with COVID-19 severity among patients on maintenance haemodialysis: a retrospective multicentre cross-sectional study in the UK. BMJ Open, 2022, 12, e054869.	1.9	4
6	Variation in Peritoneal Dialysis Time on Therapy by Country. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 861-871.	4.5	14
7	Intervening to eliminate the centre-effect variation in home dialysis use: protocol for Inter-CEPt—a sequential mixed-methods study designing an intervention bundle. BMJ Open, 2022, 12, e060922.	1.9	2
8	The osmo-metabolic approach: a novel and tantalizing glucose-sparing strategy in peritoneal dialysis. Journal of Nephrology, 2021, 34, 503-519.	2.0	17
9	Clinical utility of a traditional score system for the evaluation of the peritoneal dialysis exit-site infection in a national multicentric cohort study. Peritoneal Dialysis International, 2021, 41, 292-297.	2.3	4
10	ISPD recommendations for the evaluation of peritoneal membrane dysfunction in adults: Classification, measurement, interpretation and rationale for intervention. Peritoneal Dialysis International, 2021, 41, 352-372.	2.3	42
11	MO681PERITONEAL DIALYSIS TIME ON THERAPY AND REGIONAL DIFFERENCES IN DEATH, TRANSFER TO HEMODIALYSIS AND KIDNEY TRANSPLANTATION: RESULTS FROM THE PDOPPS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
12	A genome-wide association study suggests correlations of common genetic variants with peritoneal solute transfer rates in patients with kidney failure receiving peritoneal dialysis. Kidney International, 2021, 100, 1101-1111.	5 . 2	13
13	Renal staffs' understanding of patients' experiences of transition from peritoneal dialysis to in-centre haemodialysis and their views on service improvement: A multi-site qualitative study in England and Australia. PLoS ONE, 2021, 16, e0254931.	2.5	2
14	Barriers and opportunities to increase PD incidence and prevalence: Lessons from a European Survey. Peritoneal Dialysis International, 2021, 41, 089686082110349.	2.3	3
15	Insulin resistance in cardiovascular disease, uremia, and peritoneal dialysis. Trends in Endocrinology and Metabolism, 2021, 32, 721-730.	7.1	27
16	Trends in Peritoneal Dialysis Technique Survival, Death, and Transfer to Hemodialysis: A Decade of Data from the RDPLF. American Journal of Nephrology, 2021, 52, 318-327.	3.1	8
17	Assisted peritoneal dialysis across Europe: Practice variation and factors associated with availability. Peritoneal Dialysis International, 2021, 41, 533-541.	2.3	16
18	<i>AQP1</i> Promoter Variant, Water Transport, and Outcomes in Peritoneal Dialysis. New England Journal of Medicine, 2021, 385, 1570-1580.	27.0	34

#	Article	IF	Citations
19	Trends in assisted peritoneal dialysis over the last decade: a cohort study from the French Peritoneal Dialysis Registry. CKJ: Clinical Kidney Journal, 2020, 13, 1003-1011.	2.9	15
20	Impact of the implementation of an assisted peritoneal dialysis service on peritoneal dialysis initiation. Nephrology Dialysis Transplantation, 2020, 35, 1595-1601.	0.7	20
21	Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney International, 2020, 97, 1117-1129.	5.2	407
22	Establishing a Core Outcome Set for Peritoneal Dialysis: Report of the SONG-PD (Standardized) Tj ETQq0 0 0 rgBT Diseases, 2020, 75, 404-412.	/Overlock 1.9	10 Tf 50 6 92
23	How unmeasured confounding in a competing risks setting can affect treatment effect estimates in observational studies. BMC Medical Research Methodology, 2019, 19, 166.	3.1	14
24	Attitudes toward Peritoneal Dialysis among Peritoneal Dialysis and Hemodialysis Medical Directors. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1067-1070.	4.5	9
25	Transition between Different Renal Replacement Modalities: Gaps in Knowledge and Care—the Integrated Research Initiative. Peritoneal Dialysis International, 2019, 39, 4-12.	2.3	24
26	Peritoneal Protein Clearance Is a Function of Local Inflammation and Membrane Area Whereas Systemic Inflammation and Comorbidity Predict Survival of Incident Peritoneal Dialysis Patients. Frontiers in Physiology, 2019, 10, 105.	2.8	22
27	Estimating risk of encapsulating peritoneal sclerosis accounting for the competing risk of death. Nephrology Dialysis Transplantation, 2019, 34, 1585-1591.	0.7	13
28	United Kingdom Catheter Study – Protocol Synopsis. Peritoneal Dialysis International, 2018, 38, 113-118.	2.3	3
29	Bioimpedance-defined overhydration predicts survival in end stage kidney failure (ESKF): systematic review and subgroup meta-analysis. Scientific Reports, 2018, 8, 4441.	3.3	80
30	United Kingdom Catheter Study – Protocol Synopsis. Peritoneal Dialysis International, 2018, 38, 113-118.	2.3	5
31	FP467CHANGES IN DIALYSIS PRESCRIPTION AFFECT THE TIME COURSE OF SOLUTE TRANSPORT IN PERITONEAL DIALYSIS. Nephrology Dialysis Transplantation, 2018, 33, i194-i194.	0.7	O
32	Biocompatible Solutions and Long-Term Changes in Peritoneal Solute Transport. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1526-1533.	4.5	34
33	miR-21 Promotes Fibrogenesis in Peritoneal Dialysis. American Journal of Pathology, 2017, 187, 1537-1550.	3.8	30
34	Are Peritoneal Dialysis Center Characteristics a Modifiable Risk Factor to Improve Peritoneal Dialysis Outcomes?. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1032-1034.	4.5	5
35	Length of Time on Peritoneal Dialysis and Encapsulating Peritoneal Sclerosis — Position Paper for ISPD: 2017 Update. Peritoneal Dialysis International, 2017, 37, 362-374.	2.3	113
36	A prospective, proteomics study identified potential biomarkers of encapsulating peritoneal sclerosis in peritoneal effluent. Kidney International, 2017, 92, 988-1002.	5.2	24

#	Article	IF	CITATIONS
37	UK Renal Registry 19th Annual Report: Chapter 13 Home Therapies in 2015: National and Centre-specific Analyses. Nephron, 2017, 137, 297-326.	1.8	14
38	Peritoneal Membrane Dysfunction., 2017, , 451-460.e2.		1
39	The Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS): Unifying Efforts to Inform Practice and Improve Global Outcomes in Peritoneal Dialysis. Peritoneal Dialysis International, 2016, 36, 297-307.	2.3	107
40	Complement biomarkers in the management of peritoneal dialysis. Immunobiology, 2016, 221, 1172.	1.9	2
41	Variances in peritoneal dialysis outcomes still exist. Journal of Kidney Care, 2016, 1, 56-56.	0.1	0
42	Peritoneal inflammation precedes encapsulating peritoneal sclerosis: results from the GLOBAL Fluid Study. Nephrology Dialysis Transplantation, 2016, 31, 480-486.	0.7	47
43	Peritoneal Dialysate Glucose Load and Systemic Glucose Metabolism in Non-Diabetics: Results from the GLOBAL Fluid Cohort Study. PLoS ONE, 2016, 11, e0155564.	2.5	18
44	FP564THE ROLE OF MICRORNAS-21 AND -31 IN PERITONEAL DIALYSIS-ASSOCIATED FIBROGENESIS. Nephrology Dialysis Transplantation, 2015, 30, iii262-iii262.	0.7	0
45	ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part I – Assessment and Management of Various Cardiovascular Risk Factors. Peritoneal Dialysis International, 2015, 35, 379-387.	2.3	123
46	ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part II – Management of Various Cardiovascular Complications. Peritoneal Dialysis International, 2015, 35, 388-396.	2.3	55
47	Transition between home dialysis modalities: another piece in the jigsaw of the integrated care pathway. Nephrology Dialysis Transplantation, 2015, 30, 1781-1783.	0.7	4
48	Histological and Clinical Findings in Patients with Post-Transplantation and Classical Encapsulating Peritoneal Sclerosis: A European Multicenter Study. PLoS ONE, 2014, 9, e106511.	2.5	18
49	Analgesia dose prescribing and estimated glomerular filtration rate decline: a general practice database linkage cohort study. BMJ Open, 2014, 4, e005581-e005581.	1.9	3
50	Longitudinal Study of Small Solute Transport and Peritoneal Protein Clearance in Peritoneal Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 326-334.	4.5	26
51	Interleukin-6 Signaling Drives Fibrosis in Unresolved Inflammation. Immunity, 2014, 40, 40-50.	14.3	297
52	Independent Effects of Systemic and Peritoneal Inflammation on Peritoneal Dialysis Survival. Journal of the American Society of Nephrology: JASN, 2013, 24, 2071-2080.	6.1	161
53	Peritoneal dialysis - A. Nephrology Dialysis Transplantation, 2013, 28, i214-i225.	0.7	O
54	Towards Standardized Reporting in Studies of Encapsulating Peritoneal Sclerosis. Peritoneal Dialysis International, 2013, 33, 482-486.	2.3	6

#	Article	IF	CITATIONS
55	Proof-of-principle study to detect metabolic changes in peritoneal dialysis effluent in patients who develop encapsulating peritoneal sclerosis. Nephrology Dialysis Transplantation, 2012, 27, 2502-2510.	0.7	23
56	Cryofiltration in the Treatment of Cryoglobulinemia and HLA Antibodyâ€Incompatible Transplantation. Therapeutic Apheresis and Dialysis, 2012, 16, 91-96.	0.9	10
57	Determinants of Peritoneal Membrane Function Over Time. Seminars in Nephrology, 2011, 31, 172-182.	1.6	65
58	Mycotic aneurysm of the aorta as a complication of Bacillus Calmette-Guérin instillation. Journal of the Royal College of Physicians of Edinburgh, The, 2011, 41, 114-116.	0.6	18
59	The peritoneal osmotic conductance is low well before the diagnosis of encapsulating peritoneal sclerosis is made. Kidney International, 2010, 78, 611-618.	5. 2	91
60	Understanding the variability in Ultrafiltration Obtained with Icodextrin. Peritoneal Dialysis International, 2009, 29, 407-411.	2.3	5
61	Long-Term Changes in Solute and Water Transport. Contributions To Nephrology, 2009, 163, 15-21.	1.1	5
62	Understanding the variability in ultrafiltration obtained with icodextrin. Peritoneal Dialysis International, 2009, 29, 407-11.	2.3	5
63	Ethnicity, age and incidence rates for renal replacement therapy (RRT) in Birmingham, UK: 1990-2004. Nephrology Dialysis Transplantation, 2008, 23, 3983-3987.	0.7	12
64	Use of tunnelled haemodialysis catheters at the start of haemodialysis—success rates and definition of infection. Nephrology Dialysis Transplantation, 2007, 22, 1799-1800.	0.7	4
65	Starting and withdrawing haemodialysisâ€"associations between nephrologists' opinions, patient characteristics and practice patterns (data from the Dialysis Outcomes and Practice Patterns Study). Nephrology Dialysis Transplantation, 2006, 21, 2814-2820.	0.7	37